Is Galleri the future of cancer treatment? It's not that simple. The new research from the company, while promising, isn't ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Biohaven was seeking approval for its drug Vyglxia in the treatment of Spinocerebellar ataxia. ・The company is in the process ...

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...

Unregulated compounded GLP-1s are not the same as the legitimate medications that doctors prescribe for weight loss and chronic disease management.

The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...

Meitheal Pharmaceuticals has gotten federal approval for a new kind of antibiotic for use on hospitalized patients with ...

After a three-month delay, the FDA has now rejected an approval request based on the RWE. According to Biohaven, the FDA’s complete response letter “cited issues that can be inherent to real-world ...